Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2019 | Predicting resistance to targeted therapies in melanoma

Christian Blank • 27 Sep 2019
ESMO 2019
Melanoma Skin Cancer

Christian Blank, MD, PhD, Netherlands Cancer Institute, Amsterdam, The Netherlands, outlines how we might be able to predict resistance to targeted therapies in melanoma patients. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

More from Christian Blank

Neoadjuvant ipilimumab plus nivolumab in stage III melanoma
1:55
Neoadjuvant ipilimumab plus nivolumab in stage III melanoma
Christian Blank • 16 Apr 2021
The future of adjuvant therapy in melanoma
1:44
The future of adjuvant therapy in melanoma
Christian Blank • 19 Apr 2021
Neoadjuvant IPI + NIVO in stage III melanoma: updates from OpACIN & OpACIN-neo
1:16
Neoadjuvant IPI + NIVO in stage III melanoma: updates from OpACIN & OpACIN-neo
Christian Blank • 19 Apr 2021
OpACIN and OpACIN-neo trial updates
1:34
OpACIN and OpACIN-neo trial updates
Christian Blank • 27 Sep 2019

Related Videos

BRAF/MEK inhibition prior to immunotherapy in melanoma: insights from the COWBOY trial
1:45
BRAF/MEK inhibition prior to immunotherapy in melanoma: insights from the COWBOY trial
Kalijn Bol • 31 May 2026
COWBOY trial: optimal sequencing of BRAF/MEK inhibition and immunotherapy in BRAF-mutated melanoma
1:08
COWBOY trial: optimal sequencing of BRAF/MEK inhibition and immunotherapy in BRAF-mutated melanoma
Kalijn Bol • 31 May 2026
Could induction BRAF/MEK inhibition be useful for some melanoma patients with metastases?
1:02
Could induction BRAF/MEK inhibition be useful for some melanoma patients with metastases?
Kalijn Bol • 31 May 2026
The future of personalized and off-the-shelf mRNA vaccines in melanoma
1:02
The future of personalized and off-the-shelf mRNA vaccines in melanoma
James Smithy • 31 May 2026
The content of VJOncology is intended for healthcare professionals